Last week, drugmaker Endo International released its results for the second quarter of the year. The healthcare company posted revenue of $569.1 million in the period, a decrease of 20 per cent compared to $714 million in the second quarter of 2021. The company also reported a loss of $1.89 billion in its second quarter. Despite the fall in revenue and significant loss, the numbers exceeded the expectations of analysts. After all, the company has been lumbering from crisis to crisis in recent years over its alleged role in fuelling the opioid crisis in the United States. The company has…

Want to read the full story?

Unlock this article – and everything else on The Currency – with an annual membership and receive a free Samsonite Upscape suitcase, retailing at €235, delivered to your door.

Subscribe

Cancel at any time.

Are you already a member? .